Detalhe da pesquisa
1.
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Ann Oncol
; 26(6): 1194-1200, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25858497
2.
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Ann Oncol
; 25(9): 1762-1769, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25122671
3.
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Allergy
; 64(8): 1194-201, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19614621
4.
Masitinib is safe and effective for the treatment of canine mast cell tumors.
J Vet Intern Med
; 22(6): 1301-9, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18823406
5.
Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.
Psychopharmacology (Berl)
; 235(5): 1545-1556, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29520592
6.
Drug-induced minimal change nephropathy in a dog.
J Vet Intern Med
; 24(2): 431-5, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20136717
7.
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Vet J
; 191(1): 131-4, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21333567
8.
Safety of masitinib mesylate in healthy cats.
J Vet Intern Med
; 25(2): 297-302, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21314730
9.
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
Eur J Cancer
; 45(13): 2333-41, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19541476